UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
August 1, 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th
Floor
New
York, New York 10022
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals Grieves the Death of
Board
Member Jonathan Spicehandler, MD
New
York, NY, August 1, 2006
-
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) mourns the loss
of
board member Jonathan Spicehandler, MD. Dr. Spicehandler passed away on July
30,
2006, after a long battle with brain cancer.
A
member
of XTL's board since February 2005, Dr. Spicehandler had an illustrious
pharmaceutical career, most recently serving as Chairman of Schering-Plough
Research Institute, the pharmaceutical research arm of Schering-Plough
Corporation. Dr. Spicehandler was a prolific researcher and played a leading
role in the development and approval of several, important drugs that are used
today to treat millions of people.
“We
are
deeply saddened by the untimely passing of Jonathan Spicehandler” said Ron
Bentsur, CEO of XTL. “His leadership and experience, and above all, friendship,
will be sorely missed. Jonathan will continue to be an inspiration to all of
us.
Our deepest condolences go out to his wife and children.”
Contact:
Ron
Bentsur
Chief
Executive Officer
(212)
531-5960
rbentsur@xtlbio.com
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
|
| |
XTL
BIOPHARMACEUTICALS LTD. |
|
|
|
| Date: August
1, 2006 |
By: |
/s/ Ron
Bentsur |
| |
Ron
Bentsur |
| |
Chief
Executive Officer
|